Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BBIO
BRIDGEBIO PHARMA, INC.
NASDAQ
$76.60
▼ DOWN 2.64% (-2.08)

KEY STATISTICS

Market Cap$15.00 B
52w High$93.42
52w Low$48.78
Dividend Yield—
Frequency—
P/E-20.48
Volume1.92M
Shares Out.195.86M

COMPANY

LEADERSHIP

Neil Kumar
CHIEF EXECUTIVE
Neil Kumar

COMPENSATION 2026

Salary$1,044,000
Stock Awards$10,606,275
Incentive Plan Pay$0
All Other Comp.$15,318
Total$14,944,585

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 27, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
999

PRICE TARGET

Target High$130.00
Target Low$96.00
Target Median$106.50
Target Consensus$107.92

UPCOMING EARNINGS

DateOct 28, 2026
DayWednesday
Rev. Est.$267.31M
OCT
28
WED

PRICE

$76.60 ▼ DOWN 2.64% (−$2.08)
$76.50$78.00$79.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM76.60

About BridgeBio Pharma, Inc.

https://www.bridgebio.com ↗

BridgeBio Pharma, founded in 2015 in Palo Alto, develops medicines for genetic diseases with a pipeline of 30 programs, including treatments for TTR amyloidosis, achondroplasia, CAH, hypocalcemia, hyperoxaluria, and gene therapy, through collabora...

INDUSTRY

Biotechnology

A PRODUCT BRIDGEBIO PHARMA, INC. IS KNOWN FOR

Infigratinib
Infigratinib

Infigratinib is an investigational oral therapy for achondroplasia, with positive Phase 3 results showing increased height velocity in children, and plans to seek regulatory approval in late 2026.

COMPETITORS

COMPETITOR
ASND COMPARE
BMRN COMPARE
INCY COMPARE
JNJ COMPARE
TYRA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$108.11M $254.26M ▲$180.6M ▼$222.44M ▲
Royalty$4.28M $7.11M ▲$9.5M ▲$15.43M ▲
License and Service$8.31M $120.01M ▲$4.42M ▼$5.8M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
202
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.02% · 5.6M
XBI
1.04% · 1.6M
IBB
0.93% · 1.3M
SCHA
0.28% · 818.3K
DFAC
0.02% · 124.8K
FXH
0.84% · 124.7K
JGRO
0.10% · 121.9K
QQQJ
0.74% · 114.0K
TMSL
0.21% · 81.8K
FBAL.NE
0.09% · 72.7K
JHMM
0.09% · 68.2K
CANC
2.33% · 64.3K
LABU
0.71% · 57.1K
MIVO.L
3.88% · 45.8K
BR
BRES
0.49% · 44.1K
PB
PBPH
0.25% · 33.3K
GSC
0.83% · 29.7K
ZUH.TO
1.28% · 22.1K
BBP
1.45% · 21.9K
BKMC
0.24% · 20.6K
FSCC
0.48% · 20.2K
IQSM
0.36% · 16.1K
RECS
0.02% · 14.5K
HELX
3.39% · 14.1K
PTL
0.09% · 10.4K
BIOT.L
2.72% · 8.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
63.20%
HOLDERS
644
TOP 12 OF 644 · RANKED BY POSITION SIZE
Vanguard Group Inc
16.9M sh · $1.29B
Viking Global Investors LP
16.0M sh · $829.89M
Blackrock, Inc.
14.5M sh · $1.11B
Kohlberg Kravis Roberts & Co. L.P.
13.3M sh · $984.76M
Janus Henderson Group Plc
13.2M sh · $978.61M
Blackrock Inc.
12.4M sh · $315.31M
Farallon Capital Management LLC
10.7M sh · $800.14M
Aisling Capital Management LP
6.1M sh · $316.29M
State Street Corp
5.6M sh · $291.19M
Wellington Management Group Llp
5.3M sh · $395.41M
Geode Capital Management, LLC
4.9M sh · $371.93M
Invesco Ltd.
4.8M sh · $369.55M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-05-11

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Kumar Neil
Sale · 1.9K shares
2026-08-18
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Kumar Neil
Sale · 14.6K shares
2026-08-18
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Kumar Neil
Sale · 1.2K shares
2026-08-18
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Kumar Neil
Sale · 17.3K shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OVERWEIGHT 5
OUTPERFORM 4
NEUTRAL 1
MARKET PERFORM 1
18 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Canaccord Genuity BUY Truist Securities BUY B of A Securities BUY Morgan Stanley OVERWEIGHT Piper Sandler OVERWEIGHT TD Cowen BUY Wells Fargo OVERWEIGHT

SECTORS PEERS

PEERPRICE
MRNA$137.99COMPARE
RVMD$207.88COMPARE
ROIV$34.71COMPARE
ASND$247.91COMPARE
JAZZ$244.54COMPARE
EXEL$54.45COMPARE
BMRN$64.67COMPARE
SMMT$13.73COMPARE